RxDoctor Payments Data

Edward Portnoy, MD

Internal Medicine · Moorpark, CANPI 1295763381

Payments from drug & device makers

$1,735,193in general payments, 2019–2025

Across 133 payments — averaging $13,047 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1M
  • Novartis$374K
  • Merck$183K
  • Alnylam Pharmaceuticals Inc.$55K
  • AstraZeneca$32K
  • AbbVie$22K
  • plus $21K from 8 others
$40,257in research payments, 2019–2025

Across 9 payments — averaging $4472.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$40K

What the payments were for

  • Food & beverage$89892%
  • Education$758%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,735,193 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$86,604
Medicare patients
142
Services billed
38,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$67,115
Albendazole12$49,325
NucyntaTapentadol Hcl27$37,070
XareltoRivaroxaban39$19,023
JardianceEmpagliflozin15$16,074
TradjentaLinagliptin17$15,293
OzempicSemaglutide14$15,106
MyrbetriqMirabegron20$14,549
TrulicityDulaglutide16$13,452
MounjaroTirzepatide13$12,759
FarxigaDapagliflozin Propanediol11$12,651
Repatha SureclickEvolocumab15$12,405
SynthroidLevothyroxine Sodium82$6,347
Erythromycin Ethylsuccinate23$3,632
Sucralfate16$2,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$15,10614 claims
Astellas Pharma US IncMyrbetriq$75$14,54920 claims
AstraZenecaFarxiga$31,631$12,65111 claims
AbbVieSynthroid, Armour Thyroid$22,482$7,74797 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Moorpark

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →